IDEAS home Printed from
   My bibliography  Save this article

Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study


  • Christopher Kruse

    (University of Duisburg-Essen)

  • Sabrina Kretschmer

    (University of Duisburg-Essen
    Philipps-University Marburg)

  • Anna Lipinski

    (University of Duisburg-Essen
    Philipps-University Marburg)

  • Malte Verheyen

    (University of Duisburg-Essen)

  • David Mengel

    (University of Tübingen)

  • Monika Balzer-Geldsetzer

    (University of Duisburg-Essen
    Philipps-University Marburg)

  • Stefan Lorenzl

    (Department of Neurology, Ludwig-Maximilians University
    Paracelsus Medical University)

  • Carmen Richinger

    (Paracelsus Medical University)

  • Christian Schmotz

    (Paracelsus Medical University)

  • Lars Tönges


  • Dirk Woitalla

    (St. Josef-Krankenhaus Kupferdreh)

  • Stephan Klebe

    (Essen University Hospital)

  • Anette Schrag

    (King’s College)

  • Richard Dodel

    (University of Duisburg-Essen
    Philipps-University Marburg)


Objective The Care of Late-Stage Parkinsonism (CLaSP) study aimed to collect qualitative and standardized patient data in six European countries (France, Germany, Netherlands, Portugal, UK, Sweden) to enable a detailed evaluation of the underexplored late stages of the disease (Hoehn and Yahr stage > 3) using clinical, neuropsychological, behavioral, and health economic data. The aim of this substudy was to provide a health economic evaluation for the German healthcare system. Methods In Germany, 228 patients were included in the study. Costs were calculated from a societal perspective for a 3-month period. Univariate analyses were performed to identify cost-driving predictors. Total and direct costs were analyzed using a generalized linear model with a γ-distributed dependent variable and log link function. Indirect costs were analyzed using a binomial generalized linear model with probit link function. Results The mean costs for the 3-month period were approximately €20,000. Informal care costs and hospitalization are approximately €11,000 and €5000. Direct costs amounted to 89% of the total costs, and the share of indirect costs was 11%. Independent predictors of total costs were the duration of the disease and age. The duration of the disease was the main independent predictor of direct costs, whereas age was an independent predictor of indirect costs. Discussion Costs in the late stage of the disease are considerably higher than those found in earlier stages. Compared to the latter, the mean number of days in hospital and the need for care is increasing. Informal caregivers provide most of the care. Clinical Trial Registration The protocol was registered at as NCT02333175 on 7 January, 2015.

Suggested Citation

  • Christopher Kruse & Sabrina Kretschmer & Anna Lipinski & Malte Verheyen & David Mengel & Monika Balzer-Geldsetzer & Stefan Lorenzl & Carmen Richinger & Christian Schmotz & Lars Tönges & Dirk Woitalla , 2021. "Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study," PharmacoEconomics, Springer, vol. 39(5), pages 601-615, May.
  • Handle: RePEc:spr:pharme:v:39:y:2021:i:5:d:10.1007_s40273-021-01011-y
    DOI: 10.1007/s40273-021-01011-y

    Download full text from publisher

    File URL:
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL:
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item

    As the access to this document is restricted, you may want to search for a different version of it.


    Blog mentions

    As found by, the blog aggregator for Economics research:
    1. Journal round-up: PharmacoEconomics 39(5)
      by Don Husereau in The Academic Health Economists' Blog on 2021-07-16 06:00:06

    More about this item


    Access and download statistics


    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:39:y:2021:i:5:d:10.1007_s40273-021-01011-y. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.